Drug intelligence / Profile preview

C-20081

Development stage: Unknown
Lead developer: Concert Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

**C-20081** is a deuterated analog of the antibiotic **linezolid**, developed by **Concert Pharmaceuticals** using deuterium modification to enhance pharmacokinetic properties. It belongs to the **oxazolidinone** class and inhibits bacterial protein synthesis by binding to the **30S ribosomal subunit**, offering identical efficacy to linezolid in preclinical studies but with improved plasma half-life (43% increase), higher Cmax (70-300 ng/ml vs 14-140 ng/ml), and 81% increased AUC, potentially enabling once-daily oral or intravenous dosing for bacterial infections.[1][3][9][11][13]

Targets

IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)CK1α (Casein kinase I alpha)

Beyond the preview

Go deeper on C-20081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-20081.

Explore the full profile